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1 
 
Abstract 
Transient receptor potential vanilloid-1 (TRPV1) is a member of the TRP family of 
channels that are responsible for nociceptive, thermal and mechanical sensations. It is 
primarily associated with neuronal cells, but has been detected in different non-
neuronal cells, including leukocytes. Capsaicin (CAP), the active ingredient of hot 
chilli peppers, is one of a number of related endogenous and plant-derived 
compounds (broadly termed ‘vanilloid-like agents’) that have been shown to induce 
apoptosis and inhibit cell proliferation in some cancer cells, through both TRPV1-
dependent and -independent mechanisms. The expression and function of TRPV1 in 
haematological malignancies however, has not been extensively investigated. 
Specific targeting by vanilloid-like agents toward TRPV1 on cancerous cells in 
patients with haematological malignancies may represent a novel therapeutic 
approach to treating these diseases.  
 
This thesis investigated the expression and function of TRPV1 in haematological 
malignancies, using both blood cancer cell lines and blood samples obtained from 
patients with different blood cancers.  The specific aims were to; 1) study the effect 
of TRPV1 agonists and antagonists on the viability of THP-1, U266B1 and U937 
haematological malignant cell lines, 2) validate and optimise Western blotting and 
flow cytometry protocols to detect TRPV1 expression in leukocytes, 3) investigate 
TRPV1 expression in THP-1, U266B1 and U937 cells, and 4) compare TRPV1 
expression in leukocytes obtained from patients with blood cancers to normal 
subjects. 
2 
 
The thesis begins with a comprehensive review and discussion on TRPV1 structure 
and function, as well as its expression and role in health and disease. In particular, 
there is a focus on the role of TRPV1 in cancer, including haematological 
malignancies (Chapter 1). 
 
In Chapter 2, the effect of CAP on the metabolic activity of three malignant 
haematological cell lines, THP-1, U266B1 and U937, was investigated. Metabolic 
activity assays were performed using the alamarBlue
®
 method. CAP induced 
cytotoxicity in all three cell lines in a concentration-dependent manner. A biphasic 
effect on metabolic activity was observed on THP-1 cells [EC50, IC50 (95% CI) = 
32.9 (19.9-54.3), 219 (144-246) µM]. U266B1 cells were more resistant to CAP-
induced death than THP-1 and U937 cells. TRPV1 and CB1 antagonists (SB452533 
and AM251, respectively) suppressed the CAP-induced increase in THP-1 cell 
metabolic activity (P<0.001). These experiments suggest that CAP inhibits the 
metabolic activity of malignant haematological cells through a non-TRPV1-
dependent mechanism. 
 
Chapters 3 and 4 represent the experimental work and trouble-shooting conducted to 
develop, validate and optimise methods for the detection of TRPV1 expression in 
human cells. Western blotting (Chapter 3) and flow cytometric (Chapter 4) methods 
have been previously published, however few have documented the use of 
appropriate controls for the detection of TRPV1, suggesting that data in the literature 
may not necessarily be valid. A problem identified in the current study was the 
correct application of negative controls, particularly to assess the specificity and 
therefore suitability of the primary antibody used in these methods. These optimised 
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protocols were then used to investigate the expression of TRPV1 in human malignant 
haematological cell lines (Chapter 5) and leukocytes obtained from patients with 
blood cancers (Chapter 6).  
 
Increased expression of TRPV1 protein was observed in THP-1, U266B1 and U937 
cells compared to normal leukocytes. Furthermore, a TRPV1 dimer was detected in 
U266B1 cells. Interestingly, TRPV1 was detected in non-haematological cell lines 
that have previously been used as TRPV1-negative cells for Western blotting, 
including untransfected- and TRPV1-transfected (without tetracycline to switch 
TRPV1 transcription off) HEK293 and RAW264.7 cells. This latter finding 
highlights the need for appropriate negative (and positive) controls in both flow 
cytometric and Western blotting studies of TRPV1. 
 
Expression of TRPV1 in leukocytes obtained from patients with a range of 
haematological malignancies, including multiple myeloma (MM) and B-cell non-
Hodgkin’s Lymphoma (B-NHL), was then investigated (Chapter 6). TRPV1 
expression was detected in all patients and controls using flow cytometry, but not 
Western blotting. Using flow cytometry, a sub-group of patients (4/49=8.2%, 
MM=2, B-NHL=2) demonstrated increased expression of TRPV1 relative to the 
remainder of the cohort. TRPV1 was found to be similar to the control group for 
91.8% of all patients. There were no significant differences in TRPV1 expression 
(assessed using flow cytometry) between patients with MM and B-NHL, or between 
de novo patients and those undergoing treatment. Using Western blotting, TRPV1 
(~95kDa) was detected in one MM and four B-NHL patients, although interestingly, 
a 240kDa band was also detected in both a B-NHL and a MM patient. In addition, 
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although C-reactive protein was elevated (≥5 mg/L) in 25% of all patients, it was not 
associated with higher TRPV1 expression. These results indicate that TRPV1 
expression in leukocytes is relatively increased in a small subset of patients with 
blood cancers, and is not associated with inflammation. Furthermore, some patients 
may have a unique isoform of TRPV1 that warrants further investigation. 
 
In summary, this study has generated new data and knowledge on the role of TRPV1 
in haematological cells, including those from patients with blood cancers. A number 
of novel findings have been reported. Firstly, the inhibition of cell metabolic activity 
by the TRPV1 agonist, CAP, was found to be independent of TRPV1 activation in 
malignant haematological cell lines. Secondly, optimised Western blotting and flow 
cytometric methods for the detection of TRPV1 expression were developed and 
successfully validated. Thirdly, increased TRPV1 expression was demonstrated in 
the THP-1, U266B1 and U937 malignant haematological cell lines. Finally, 
increased TRPV1 expression was observed in some patients with MM and B-NHL, 
but was not associated with inflammation. The results presented in this thesis can be 
used as a basis for future studies of TRPV1 function in other human cells and 
cancers. 
 
